#China #Shanghai #Hengrui Pharma #ASCO 2025 #Cancer Innovation

Hengrui Pharma's Significant Role at the 2025 ASCO Annual Meeting

The 2025 ASCO (American Society of Clinical Oncology) Annual Meeting unfolded successfully in Chicago, concluding on June 3rd, 2025. This noteworthy event witnessed Hengrui Pharma making a remarkable impact by presenting an impressive array of research and innovative therapeutic options in oncology.

Hengrui Pharma showcased 15 groundbreaking drugs and provided 72 research outcomes, which included 4 oral presentations, 5 rapid oral presentations, 27 poster presentations, and 36 online publications. These contributions ignited extensive discussions among leading global experts in the field, underlining the company's pivotal role in cancer research and treatment.

Advancements in Breast Cancer Treatment

In breast cancer research, Hengrui highlighted the results from a total of 19 studies centered on their innovative cancer treatments, including pyrotinib, dalpiciclib, camrelizumab, apatinib, adebrelimab, Trastuzumab rezetecan (SHR-A1811), and SHR-2017. The efficacy of these drugs was presented in various combinations with each other and with traditional chemotherapy agents. Seven studies featuring pyrotinib and six studies featuring dalpiciclib stood out prominently, reaffirming the effectiveness of these agents in breast cancer treatment.

Additionally, studies focused on SHR-A1811 and adebrelimab garnered attention during rapid oral presentations, emphasizing their potential impact on improving patient outcomes in breast cancer and enhancing clinical practice norms in oncology.

Gastrointestinal Cancer Innovations

In the realm of gastrointestinal cancers, Hengrui's presentation included a robust total of 30 studies featuring critical drugs like camrelizumab, apatinib, adebrelimab, and SHR-8068. Camrelizumab appeared in 21 of these studies, showcasing its extensive therapeutic profiles and confirming its significance as a major focus at the ASCO meeting. These findings reflect the global recognition and achievements of China-developed PD-1 inhibitors.

Furthermore, adebrelimab's forward momentum in lung cancer research has inspired exploration into new domains, with five studies presented this year looking into its effectiveness for treating hepatocellular carcinoma, cholangiocarcinoma, and pancreatic cancer. Such research indicates promising avenues for enhancing clinical care in gastrointestinal oncology.

Comprehensive Oncology Portfolio

Hengrui's innovative oncology portfolio, featuring drugs like camrelizumab, apatinib, adebrelimab, pyrotinib, dalpiciclib, fluzoparib, and many others, was the subject of 22 research presentations, which included 4 oral presentations, 2 rapid oral presentations, 12 poster displays, and 4 online publications. This impressive output underscores Hengrui's robust research and development capabilities, with a notable online publication demonstrating the efficacy of ondansetron oral soluble film in managing chemotherapy-induced nausea and vomiting (CINV).

This year marks the 15th consecutive year that Hengrui has presented its pioneering research at ASCO, further asserting their leadership in the oncology drug sector globally. The presence of 70 studies sponsored by Hengrui at this year’s meeting reflects the solid foundations established by their lineup of 23 marketed innovative drugs and an extensive pipeline housing over 90 candidates currently undergoing development.

Looking forward, Hengrui Pharma remains steadfast in its patient-centered mission, committed to developing advanced therapeutics that align with the